Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 693-urinary-stones-with-mcc
    Ask Trek AI about this page

    Urinary Stones with MCC: Inpatient Reimbursement Overview

    DRG 693 addresses inpatient admissions for urinary stones complicated by a Major Complication or Comorbidity, such as severe infection or acute renal failure, that increases resource needs. This grouping matters for inpatient reimbursement because it assigns higher payment weights to reflect greater intensity of care, longer stays, and increased costs under Medicare payment rules.

    Customize your policy alerts

    Sign up for drg 693 policy alerts

    Get alerted when payer policies referencing 693 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 693 Overview

    DRG 693 covers inpatient admissions for urinary stones with a Major Complication or Comorbidity where the presence of a significant secondary condition increases resource use. Typical clinical scenarios include obstructing renal or ureteral calculi with severe infection, sepsis, acute renal failure, or other major comorbid conditions requiring intensified inpatient management. This Diagnosis-Related Group influences Medicare payment by assigning higher relative weight and reimbursement to reflect increased intensity of care, extended length of stay, and greater resource consumption. Understanding this classification is important for accurate case grouping and hospital revenue integrity under Medicare inpatient prospective payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute procedural and perioperative trials evaluating optimized surgical or endourological techniques (eg, comparisons of lithotripsy energy settings, ureteroscopy approaches, or timing of stent placement) in hospitalized patients with urinary stones complicated by major comorbidities. These studies enroll patients admitted for obstructing stones with systemic complications (eg, sepsis, acute kidney injury, or severe cardiac/pulmonary disease) to assess procedural success, complication rates, and short-term recovery metrics. Results inform clinicians about safest, most effective acute interventions for high-risk inpatients and help payers understand resource use, length of stay, and complication-driven costs tied to specific procedural strategies.
    • Comparative effectiveness and risk-stratification studies that examine conservative versus interventional management in medically complex patients with urinary stones, often using registry or observational cohorts. These trials focus on older adults or patients with significant MCC (eg, CKD, heart failure, or coagulopathy) to determine which patients benefit from immediate invasive management versus delayed or medical therapies, and to identify predictors of readmission and deteriorating renal function. Findings are relevant to providers making individualized care decisions and to payers designing guidelines and bundled payment models that balance clinical benefit with avoidance of preventable complications and readmissions.
    • Post-discharge outcomes and care coordination research assessing transitional care, secondary prevention, and long-term renal outcomes in survivors of complicated stone admissions. Studies follow discharged patients with prior obstructing stones and MCC to evaluate adherence to metabolic evaluation, recurrence rates, chronic kidney disease progression, and the impact of outpatient care pathways (eg, care navigation, nephrology follow-up) on readmissions and downstream costs. This research helps health systems and payers target interventions that reduce recurrent hospitalizations and long-term morbidity in a high-cost DRG population.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.